Roche Diagnostics has acquired Constitution Medical Inc.
2 July 2013 | By Roche
Strengthening Roche's commitment to hematology testing...
List view / Grid view
News
Merck receives Complete Response Letter for Suvorexant, Merck’s investigational medicine for insomnia
1 July 2013 | By Merck
“We will evaluate the requests outlined in the Complete Response Letter..."
FDA approves new U.S. labeling for ISENTRESS® (raltegravir)
1 July 2013 | By Merck
New U.S. labeling for ISENTRESS® (raltegravir) to include 240-week results from STARTMRK study...
GSK receives positive CHMP opinions for Tafinlar® (dabrafenib) and Tyverb® (lapatinib)
28 June 2013 | By GlaxoSmithKline
The EMA's CHMP is recommending marketing authorisation for two cancer drugs...
Genzyme receives positive CHMP opinion for LEMTRADA™ in Europe
28 June 2013 | By Sanofi
"Today’s CHMP opinions set the stage for the approval of two important new treatment options..."
Lyxumia® is first diabetes therapy of its class approved in Japan for use in combination with basal insulin
28 June 2013 | By Sanofi
Japan’s MHLW has approved the manufacturing and distribution of Lyxumia®...
AstraZeneca completes acquisition of Pearl Therapeutics
28 June 2013 | By AstraZeneca
AstraZeneca announced that on 27 June 2013 it completed its acquisition of Pearl Therapeutics...
Innovative genetic treatment to prevent mitochondrial disease
28 June 2013 | By Department of Health
Public consultation expected on draft regulations for IVF-based techniques to prevent mitochondrial disease later this year...
CHMP recommends EU approval of Roche’s subcutaneous Herceptin for HER2 positive breast cancer
28 June 2013 | By Roche
"Over the last 14 years, Herceptin has revolutionised the treatment of HER2-positive breast cancer..."
GSK’s drisapersen to receive FDA breakthrough therapy designation for potential treatment of patients with DMD
27 June 2013 | By GlaxoSmithKline
GlaxoSmithKline has received a verbal notification...
GSK and Save the Children launch $1 million award to discover new healthcare innovations for reducing child deaths
27 June 2013 | By GSK
GSK and Save the Children today launched a $1 million Healthcare Innovation Award...
Rapid Micro Biosystems secures $32.6 million in series B financing
26 June 2013 | By Rapid Micro Biosystems
Rapid Micro Biosystems announced that it has raised $32.6 million in series B financing...
Novartis reports new Phase III data showing omalizumab significantly improves itch in patients with severe form of chronic skin disease CSU[1]
26 June 2013 | By Novartis
Novartis announced late-breaking results...
Rigaku Raman delivers new software enhancements to its Xantus-2 portable analyzer
25 June 2013 | By Rigaku
Rigaku Raman Technologies has announced software enhancements to its leading Xantus-2™ dual-wavelength portable Raman analyzer...
Results of new meta-analysis regarding CV events in linagliptin Phase 3 trials presented at ADA
25 June 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with an increased risk of cardiovascular events in the treatment of Type 2 Diabetes (T2D), versus a number of…
